Cancer Focus Fund Managing Partner Ross Barrett was pleased to join Barry Burgdorf and the Hogan Lovells team at the J.P. Morgan Healthcare Conference to discuss opportunities under the new administration for venture capital and private equity investing in emerging life sciences fields. #JPM25 #JPMorgan #Healthcare #Biotech
Cancer Focus Fund
投资管理
Houston，Texas 191 位关注者
Supporting promising new cancer treatments in partnership with The University of Texas MD Anderson Cancer Center
关于我们
The Cancer Focus Fund is an oncology-focused investment fund which invests in compelling cancer therapies at or near the FDA Phase 1 or Phase 2 human clinical trial regimen. The fund offers business, management, IP, clinical, scientific and regulatory support through experienced and proven professionals. At the Cancer Focus Fund, we invest in promising therapies in late preclinical development through Phase I and Phase Ib/II clinical trials. Our objective is to provide support to accelerate the development of these therapeutics together with the clinical trials expertise and infrastructure of MD Anderson. Through our unique approach, we believe the Cancer Focus Fund has the potential to bring more treatments to patients in need while also rewarding our investors.
- 网站
-
https://cancerfocusfund.com/
Cancer Focus Fund的外部链接
- 所属行业
- 投资管理
- 规模
- 2-10 人
- 总部
- Houston，Texas
- 类型
- 合营企业
地点
Cancer Focus Fund员工
-
Ross Barrett
General Partner @ Cancer Focus Fund | Investment, Clinical Trials
-
Jaime Aguirre
Private Equity Investor - Fund Management and Direct Investments
-
Jennifer Preis Pou
Associate at Cancer Focus Fund, BVM Capital Partners
-
Hector Alila
Founder, Chairman and CEO, Remunity Therapeutics, Inc.
动态
-
Cancer Focus Fund is excited to announce its investment in Starget Pharma, an early-stage clinical company developing a new class of Smart Targeted Radioligands for precision oncology of hard-to-heal cancers.?The Cancer Focus Fund investment will support a Phase 1b clinical trial of Starget’s lead theranostic, DOTA-PTR-58.
?? Big News from Starget Pharma! ?? We’re excited to announce a $5.1M investment from Cancer Focus Fund, a unique venture capital fund that partners with MD Anderson Cancer Center to accelerate innovative cancer therapies. This funding will support the Phase 1b trial of DOTA-PTR-58, our pioneering First-in-Class Radioligand Therapy (RLT) targeting SSTR-3 receptors in cancers like sarcoma, melanoma, and neuroendocrine tumors. The trial will be conducted with MD Anderson, the US #1 cancer hospital (U.S. News & World Report), recognized worldwide for its leadership in cancer care, research, and education. Together with Cancer Focus Fund’s strategic investment and MD Anderson’s expertise, we’re advancing the future of radioligand therapies to address unmet needs in oncology. Special thanks to the Cancer Focus Fund and MD Anderson Team's including Ross Barrett, Jennifer Preis Pou, Jonathan Fassberg, Shara Avis Pecoraro (MHA, MSJ) , Barry Burgdorf,H. Charles Manning, Jordi Rodón, Jean K. Gilbert, Brooke Graham, Jubi Nair, Sharon Kaplinsky Star Tree Ventures Ltd. and to all our partners - let’s keep driving innovation and transforming the future of cancer treatment together! Phase 1b begins in early 2025 – stay tuned for updates! Learn more about Starget Pharma: https://stargetpharma.com/ Read more in our press release: https://lnkd.in/dDTDcXEF #StargetPharma #MDAnderson #CancerFocusFund #CancerResearch #Theranostics #RadioligandTherapy #PrecisionOncology #NuclearMedicine #EndCancer
-
-
Thanks to Oppenheimer & Co. Inc. and MD Anderson Cancer Center for a great conference last week in Houston. Proud that the Cancer Focus Fund is playing its small part in bringing new and innovative therapies to patients. And thanks to our CEO entrepreneurs and SAB members we couldn’t do it without you. Mereo BioPharma Nectin Therapeutics ImmunoGenesis, Inc. March Biosciences Eisbach Bio GmbH Starget Pharma Mongoose Bio Inc. KAHR-Medical Ltd. Tomer Cohen Keren Paz Michael Curran Sarah Hein Jonathan Fassberg Michael Margolis Sigal Kalmanson Cusnir Ronen Kalmanson Neil Warma Cassian Yee Barry Burgdorf Andrew Strong Ferran Prat Escude Shara Avis Pecoraro (MHA, MSJ) Ross Barrett Jennifer Preis Pou Tim Heffernan Jason Bock Marc Matrana MD, MSc, FACP Ochsner LSU Health
?????????????? ???????????????? ????????????: The Cancer Focus Fund is closing on its second fund - it's a unique model that helps companies with knowhow and trial support at MD Anderson. General Partner Ross Barrett talks about how a new, larger fund will enable them to invest in more companies, and he shares some technologies that excite him today. Full video: https://lnkd.in/gGjEzcMh This coverage is brought to you by Oppenheimer & Co. Inc. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | HSBC Innovation Banking
-
Can Investors Both Earn Returns and End Cancer? Our Managing Partner, Ross Barrett, spoke on Chief Investment Officer's webinar on this topic. https://lnkd.in/gZxFuDJR